Cancer Immunotherapy Laboratory

The goal of the Cancer Immunotherapy Laboratory, led by William L. Redmond, Ph.D., is to elucidate the mechanisms by which T cell agonists (e.g., anti-OX40 mAb) plus checkpoint blockade (e.g., anti-PD-1, anti-CTLA-4 mAb) synergize to augment tumor-specific CD8 T cell responses. Ultimately, understanding how immunotherapies enable killer CD8 T cells to destroy tumors will help guide the development of novel and more effective cancer therapies. Read more.


Cancer Immunotherapy Laboratory team, pictured left to right:

Dana Emerson, OHSU Graduate Student
Ian Hilgart-Martiszus, Research Associate
Elizabeth R. Sturgill, Ph.D., Postdoctoral Fellow
Joshua Walker, M.D., Ph.D., Research Fellow
Melissa J. Kasiewicz, Research Associate and Lab Manager
William L. Redmond, Ph.D., Associate Member
Courtney Mick, Research Associate
Mohammad Farhad, OHSU Graduate Student